Target intelligence / Profile preview

Off-target genomic loci of Actin alpha 2 (ACTA2)-directed single guide RNA (sgRNA) (ACTA2 sgRNA off-targets)

Target
ACTA2 sgRNA off-targets
Molecular classification
Genomic DNA, Non-target loci
01

Overview

Off-target genomic loci of ACTA2-directed sgRNA refer to unintended DNA sequences that share partial homology with the single guide RNA (sgRNA) designed to target the ACTA2 gene. ACTA2, which encodes alpha-smooth muscle actin, is a critical gene involved in vascular contractility and is often targeted in research related to thoracic aortic aneurysms and fibrotic diseases (UniProt P62736). During CRISPR-Cas9 mediated editing, the Cas9 enzyme may recognize and cleave these off-target sites due to sequence similarity, leading to permanent mutations such as insertions or deletions (PubMed 25513782). These genomic alterations pose significant safety risks, including the potential for insertional mutagenesis or the disruption of essential regulatory elements (PubMed 28504668). In the context of therapeutic development, identifying and minimizing these off-target effects is crucial to prevent adverse outcomes such as oncogenesis or impaired cellular function (PubMed 19409525). Monitoring these sites typically involves high-throughput sequencing methods like GUIDE-seq and CIRCLE-seq to ensure the specificity and safety of the genetic intervention (PubMed 28504668).

Other names
ACTA2 CRISPR off-targetsUnintended Cas9 cleavage sitesHomologous genomic sequencesNon-specific sgRNA binding sites
02

Mechanism of action

Unintended DNA cleavage and subsequent repair via non-homologous end joining (NHEJ) or homology-directed repair (HDR) at genomic sites with sequence similarity to the ACTA2 target sequence.

03

Biological functions

None
04

Disease associations

GenotoxicityCarcinogenesisMutagenesis
05

Safety considerations

Chromosomal translocationsInactivation of tumor suppressor genesActivation of proto-oncogenesCellular toxicityP53-mediated DNA damage response
06

Interacting drugs

CRISPR-Cas9 gene editing systems

3 more in the full profile.

07

Biomarkers

Indel frequency at off-target sitesGUIDE-seq read countsCIRCLE-seq enrichmentDigenome-seq analysis

Beyond the preview

Go deeper on Off-target genomic loci of Actin alpha 2 (ACTA2)-directed single guide RNA (sgRNA) (ACTA2 sgRNA off-targets).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Off-target genomic loci of Actin alpha 2 (ACTA2)-directed single guide RNA (sgRNA) (ACTA2 sgRNA off-targets).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call